Diabetes and Cancer

Steven Scott Coughlin, Edward L. Giovannucci

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Diabetes mellitus and associated conditions such as hyperglycaemia and hyperinsulinaemia have been associated with risk of several cancers including pancreatic, colorectal, endometrial and liver cancer. Associations identified with other cancer sites in epidemiological studies are suggestive. It is unknown whether the association between diabetes and some cancers is largely due to shared factors such as obesity and inactivity, or whether the specific metabolic derangements associated with diabetes such as hyperinsulinaemia and hyperglycaemia directly increases cancer risk. Nevertheless, as obesity and physical inactivity are the main determinants of insulin resistance and hyperinsulinaemia, the public health importance of these findings is clear. Evidence-based interventions that increase physical activity and reduce obesity in clinical settings and in communities are likely to have beneficial effects on risk of diabetes and several common cancers. Of particular interest for aetiological research are the studies that have shown that the insulin-like growth factor I (IGF-I) axis is related to cancer risk. Increases in circulating levels of IGF-1 have been observed in several epidemiological studies of colorectal, prostate and breast cancer. Clinicians who treat cancer patients must consider the cardiac, hepatic, renal and neurological complications that are commonly seen among patients with diabetes. Evidence from clinical trials and population-based studies suggests that, after a cancer diagnosis and treatment, patients with diabetes experience higher mortality and cancer recurrence rates than those without. Patients with hyperglycaemia or diabetes who undergo cancer treatment may be more likely to experience certain side effects than patients who do not have hyperglycaemia or diabetes. A growing body of evidence suggests that metformin protects against the development of certain cancers and may improve prognosis in patients with breast cancer. Randomized trials to test these hypotheses are currently ongoing.

Original languageEnglish (US)
Title of host publicationDiabetes
Subtitle of host publicationChronic Complications: Third Edition
PublisherWiley-Blackwell
Pages294-305
Number of pages12
ISBN (Print)9780470656181
DOIs
StatePublished - Apr 19 2012
Externally publishedYes

Fingerprint

Neoplasms
Hyperglycemia
Hyperinsulinism
Obesity
Insulin-Like Growth Factor I
Epidemiologic Studies
Colorectal Neoplasms
Breast Neoplasms
Metformin
Liver Neoplasms
Endometrial Neoplasms
Pancreatic Neoplasms
Insulin Resistance
Prostatic Neoplasms
Diabetes Mellitus
Public Health
Clinical Trials
Exercise
Kidney
Recurrence

Keywords

  • Antidiabetic drugs
  • Breast neoplasms
  • Colorectal neoplasms
  • Diabetes mellitus
  • Insulin
  • Insulin-like growth factor
  • Pancreatic neoplasms
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Coughlin, S. S., & Giovannucci, E. L. (2012). Diabetes and Cancer. In Diabetes: Chronic Complications: Third Edition (pp. 294-305). Wiley-Blackwell. https://doi.org/10.1002/9781118405550.ch14

Diabetes and Cancer. / Coughlin, Steven Scott; Giovannucci, Edward L.

Diabetes: Chronic Complications: Third Edition. Wiley-Blackwell, 2012. p. 294-305.

Research output: Chapter in Book/Report/Conference proceedingChapter

Coughlin, SS & Giovannucci, EL 2012, Diabetes and Cancer. in Diabetes: Chronic Complications: Third Edition. Wiley-Blackwell, pp. 294-305. https://doi.org/10.1002/9781118405550.ch14
Coughlin SS, Giovannucci EL. Diabetes and Cancer. In Diabetes: Chronic Complications: Third Edition. Wiley-Blackwell. 2012. p. 294-305 https://doi.org/10.1002/9781118405550.ch14
Coughlin, Steven Scott ; Giovannucci, Edward L. / Diabetes and Cancer. Diabetes: Chronic Complications: Third Edition. Wiley-Blackwell, 2012. pp. 294-305
@inbook{24113f58110f4f9090f5048d55f15226,
title = "Diabetes and Cancer",
abstract = "Diabetes mellitus and associated conditions such as hyperglycaemia and hyperinsulinaemia have been associated with risk of several cancers including pancreatic, colorectal, endometrial and liver cancer. Associations identified with other cancer sites in epidemiological studies are suggestive. It is unknown whether the association between diabetes and some cancers is largely due to shared factors such as obesity and inactivity, or whether the specific metabolic derangements associated with diabetes such as hyperinsulinaemia and hyperglycaemia directly increases cancer risk. Nevertheless, as obesity and physical inactivity are the main determinants of insulin resistance and hyperinsulinaemia, the public health importance of these findings is clear. Evidence-based interventions that increase physical activity and reduce obesity in clinical settings and in communities are likely to have beneficial effects on risk of diabetes and several common cancers. Of particular interest for aetiological research are the studies that have shown that the insulin-like growth factor I (IGF-I) axis is related to cancer risk. Increases in circulating levels of IGF-1 have been observed in several epidemiological studies of colorectal, prostate and breast cancer. Clinicians who treat cancer patients must consider the cardiac, hepatic, renal and neurological complications that are commonly seen among patients with diabetes. Evidence from clinical trials and population-based studies suggests that, after a cancer diagnosis and treatment, patients with diabetes experience higher mortality and cancer recurrence rates than those without. Patients with hyperglycaemia or diabetes who undergo cancer treatment may be more likely to experience certain side effects than patients who do not have hyperglycaemia or diabetes. A growing body of evidence suggests that metformin protects against the development of certain cancers and may improve prognosis in patients with breast cancer. Randomized trials to test these hypotheses are currently ongoing.",
keywords = "Antidiabetic drugs, Breast neoplasms, Colorectal neoplasms, Diabetes mellitus, Insulin, Insulin-like growth factor, Pancreatic neoplasms, Prostatic neoplasms",
author = "Coughlin, {Steven Scott} and Giovannucci, {Edward L.}",
year = "2012",
month = "4",
day = "19",
doi = "10.1002/9781118405550.ch14",
language = "English (US)",
isbn = "9780470656181",
pages = "294--305",
booktitle = "Diabetes",
publisher = "Wiley-Blackwell",
address = "United States",

}

TY - CHAP

T1 - Diabetes and Cancer

AU - Coughlin, Steven Scott

AU - Giovannucci, Edward L.

PY - 2012/4/19

Y1 - 2012/4/19

N2 - Diabetes mellitus and associated conditions such as hyperglycaemia and hyperinsulinaemia have been associated with risk of several cancers including pancreatic, colorectal, endometrial and liver cancer. Associations identified with other cancer sites in epidemiological studies are suggestive. It is unknown whether the association between diabetes and some cancers is largely due to shared factors such as obesity and inactivity, or whether the specific metabolic derangements associated with diabetes such as hyperinsulinaemia and hyperglycaemia directly increases cancer risk. Nevertheless, as obesity and physical inactivity are the main determinants of insulin resistance and hyperinsulinaemia, the public health importance of these findings is clear. Evidence-based interventions that increase physical activity and reduce obesity in clinical settings and in communities are likely to have beneficial effects on risk of diabetes and several common cancers. Of particular interest for aetiological research are the studies that have shown that the insulin-like growth factor I (IGF-I) axis is related to cancer risk. Increases in circulating levels of IGF-1 have been observed in several epidemiological studies of colorectal, prostate and breast cancer. Clinicians who treat cancer patients must consider the cardiac, hepatic, renal and neurological complications that are commonly seen among patients with diabetes. Evidence from clinical trials and population-based studies suggests that, after a cancer diagnosis and treatment, patients with diabetes experience higher mortality and cancer recurrence rates than those without. Patients with hyperglycaemia or diabetes who undergo cancer treatment may be more likely to experience certain side effects than patients who do not have hyperglycaemia or diabetes. A growing body of evidence suggests that metformin protects against the development of certain cancers and may improve prognosis in patients with breast cancer. Randomized trials to test these hypotheses are currently ongoing.

AB - Diabetes mellitus and associated conditions such as hyperglycaemia and hyperinsulinaemia have been associated with risk of several cancers including pancreatic, colorectal, endometrial and liver cancer. Associations identified with other cancer sites in epidemiological studies are suggestive. It is unknown whether the association between diabetes and some cancers is largely due to shared factors such as obesity and inactivity, or whether the specific metabolic derangements associated with diabetes such as hyperinsulinaemia and hyperglycaemia directly increases cancer risk. Nevertheless, as obesity and physical inactivity are the main determinants of insulin resistance and hyperinsulinaemia, the public health importance of these findings is clear. Evidence-based interventions that increase physical activity and reduce obesity in clinical settings and in communities are likely to have beneficial effects on risk of diabetes and several common cancers. Of particular interest for aetiological research are the studies that have shown that the insulin-like growth factor I (IGF-I) axis is related to cancer risk. Increases in circulating levels of IGF-1 have been observed in several epidemiological studies of colorectal, prostate and breast cancer. Clinicians who treat cancer patients must consider the cardiac, hepatic, renal and neurological complications that are commonly seen among patients with diabetes. Evidence from clinical trials and population-based studies suggests that, after a cancer diagnosis and treatment, patients with diabetes experience higher mortality and cancer recurrence rates than those without. Patients with hyperglycaemia or diabetes who undergo cancer treatment may be more likely to experience certain side effects than patients who do not have hyperglycaemia or diabetes. A growing body of evidence suggests that metformin protects against the development of certain cancers and may improve prognosis in patients with breast cancer. Randomized trials to test these hypotheses are currently ongoing.

KW - Antidiabetic drugs

KW - Breast neoplasms

KW - Colorectal neoplasms

KW - Diabetes mellitus

KW - Insulin

KW - Insulin-like growth factor

KW - Pancreatic neoplasms

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84884944633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884944633&partnerID=8YFLogxK

U2 - 10.1002/9781118405550.ch14

DO - 10.1002/9781118405550.ch14

M3 - Chapter

SN - 9780470656181

SP - 294

EP - 305

BT - Diabetes

PB - Wiley-Blackwell

ER -